Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1: Participants who completed the open-label extensions (OLEs) of studies WN25203 or WN28745 will be eligible to participate in Part 1 of the study
Part 2: All participants who have completed Week 104 visit in Part 1 will be eligible for Part 2 of the study
For Part 1 and Part 2:
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 16 weeks after the last dose of study drug
Agreement to not donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug
Availability of a person ('caregiver') who in the investigator's judgement, has frequent and sufficient contact with the participant
You may not be if
Prematurely discontinued from the OLEs of studies WN25203 or WN28745 or from study drug for any reason
Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
If the participant is unlikely to benefit from gantenerumab therapy, based on disease progression or other factors, or if study participation is otherwise not in the participant's best interest
Any investigational treatment other than gantenerumab during or since completion of the OLEs of studies WN25203 or WN28745
Pregnancy
Evidence of disseminated leptomeningeal hemosiderosis (i.e., more than three focal leptomeningeal hemosiderosis)
Evidence of intracerebral macrohemorrhage
Part 2: Participants who have been discontinued from Part 1 of the study
Clareo Health | A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
